ストックスクリーナーアプリを入手
1.77
4.84%
-0.09
アフターアワーズ：
1.70
-0.07
-3.95%
Cellectar Biosciences Inc (CLRB) 最新ニュース
Cellectar Biosciences Inc reports results for the quarter ended September 30Earnings Summary - XM
Cellectar Biosciences, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Cellectar corrects accounting firm consent in SEC filing By Investing.com - Investing.com Australia
Cellectar Biosciences, Inc. (NASDAQ:CLRB) Short Interest Update - MarketBeat
Cellectar Biosciences Reports Financial Results for Q3 2024 and Provides a Corporate Update - The Bakersfield Californian
Cellectar Reports Positive Phase 2 Results, Secures $19.4M in Warrant Exercises | CLRB Stock News - StockTitan
SEC Form 10-Q filed by Cellectar Biosciences Inc. - Quantisnow
Cellectar Biosciences (CLRB) Scheduled to Post Earnings on Monday - Defense World
Cellectar Biosciences Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits - Quantisnow
ADAR1 Capital Management, LLC Expands Stake in Cellectar Bioscie - GuruFocus.com
Cellectar Biosciences and NorthStar Medical Radioisotopes Announce Partnership for Supply of Actinium-225 - GlobeNewswire
Cellectar Partners With NorthStar For Ac-225 Supply - Contract Pharma
Cellectar secures Ac-225 supply for cancer drug development - Investing.com
Cellectar Secures 10-Year Supply of Rare Cancer Treatment Isotope for Clinical Trials | CLRB Stock News - StockTitan
Cellectar Biosciences and SpectronRx Partner to Manufacture - GlobeNewswire
Cellectar Biosciences (CLRB) Scheduled to Post Quarterly Earnings on Monday - MarketBeat
Cellectar Biosciences and SpectronRx Partner to Manufacture Novel Phospholipid Radioconjugate for the Treatment of Cancer - The Manila Times
CLRB (Cellectar Biosciences) 3-Year EBITDA Growth Rate : 25.40% (As of Jun. 2024) - GuruFocus.com
Cellectar Biosciences to Report Third Quarter Financial Results and Host a Conference Call on Monday, November 18, 2024 - The Manila Times
Cellectar Biosciences to Report Third Quarter Financial - GlobeNewswire
Cellectar Selected to Present New Data from Phase 2 CLOVER-WaM Study in Oral Session at ASH 2024 - GlobeNewswire
Cellectar's Breakthrough WM Cancer Drug Data Set for Major ASH 2024 Presentation | CLRB Stock News - StockTitan
Rosalind Advisors Inc. Increases Stake in Cellectar Biosciences, Inc. (NASDAQ:CLRB) - MarketBeat
Cellectar Biosciences Announces Compliance Regarding Filing of Form 10-Q - GlobeNewswire
Sequoia Financial Advisors LLC Purchases New Stake in Cellectar Biosciences, Inc. (NASDAQ:CLRB) - Defense World
Current and Future Analysis of Neuroblastoma Therapeutic - openPR
Waldenstrom Macroglobulinemia Market to Show Remarkable - openPR
Cellectar Biosciences (NASDAQ:CLRB) Stock Price Crosses Above 50-Day Moving AverageHere's What Happened - MarketBeat
Cellectar Biosciences, Inc. (NASDAQ:CLRB) Sees Large Increase in Short Interest - MarketBeat
Bone Cancer Drugs Market Next-Generation Dynamic Growth - openPR
Cellectar Biosciences (NASDAQ:CLRB) Receives Outperform Rating from Oppenheimer - Defense World
Cellectar Biosciences (NASDAQ:CLRB) Given Outperform Rating at Oppenheimer - MarketBeat
Oppenheimer maintains Outperform rating on Cellectar Biosciences By Investing.com - Investing.com Canada
Cellectar Biosciences (NASDAQ:CLRB) Shares Cross Above Fifty Day Moving Average – Here’s Why - Defense World
Cellectar Biosciences (NASDAQ:CLRB) Stock Passes Above 50 Day Moving AverageTime to Sell? - MarketBeat
ROTH to Host 3rd Annual Healthcare Opportunities Conference on October 9 in New York City - GlobeNewswire
XTX Topco Ltd Purchases 51,413 Shares of Cellectar Biosciences, Inc. (NASDAQ:CLRB) - Defense World
Cellectar Biosciences (NASDAQ:CLRB) Upgraded at StockNews.com - Defense World
Cellectar Biosciences (NASDAQ:CLRB) Upgraded to "Sell" by StockNews.com - MarketBeat
Cellectar Biosciences (NASDAQ:CLRB) Stock Quotes, Forecast and News Summary - Benzinga
Was there any good news for Cellebrite DI Ltd (CLBT) stock in the last session? - US Post News
Trust Investment Advisors Acquires Shares of 24,250 Celestica Inc. (NYSE:CLS) - MarketBeat
Cellucare Reviews (DO NOT BUY YET) Any Side Effects or Customer Complaints in 2024? - Businessday
Cardlytics Inc [NASDAQ: CDLX] Sees Increase in Stock Value - Knox Daily
CLS’s Stock Journey: What Investors Need to Know About Celestica, Inc.’s Performance - The InvestChronicle
Ratios Revealed: Decoding Celestica, Inc. (CLS)’s Financial Health - The Dwinnex
Celestica, Inc. (CLS) presents a great opportunity, but the stock is slightly undervalued - US Post News
Cellecor Gadgets Limted acquires 100% equity of Cellecor Foundation towards its CSR initiatives and commitments - APN News
Cellecor Gadgets shares rally 5% to hit new 52-week high; check key trigger - ET Now
Renaissance Technologies LLC Sells 12,126 Shares of Chemed Co. (NYSE:CHE) - Defense World
Cellectis (NASDAQ:CLLS) Coverage Initiated by Analysts at StockNews.com - Defense World
Cellecor Gadgets Ltd. Acquires Full Equity of Cellecor Foundation for CSR Initiatives - IndiaCSR
Cellecor Gadgets shares update on CSR initiatives after announcing new collaborationsDetails - India.com
Cell C in big fight with oldest shareholder - MyBroadband
Cellectar Biosciences (NASDAQ:CLRB) Rating Increased to Sell at StockNews.com - Defense World
Cemtrex (NASDAQ:CETX) Now Covered by StockNews.com - Defense World
10:1 stock split & 585 per cent returns: Penny stock under Rs 65 to keep under radar as company acquires 100 per cent in Cellecor Foundation for CSR Activities - Dalal Street Investment Journal
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates CBZ, MNTX, SBT on Behalf of Shareholders - ForexTV.com
Carter's Stock Gains 10.5% In A Month: Should You Buy, Hold Or Sell? - Barchart
There is no doubt that Celldex Therapeutics Inc. (CLDX) ticks all the boxes. - SETE News
3.66%
1.11%
大文字化:
|
ボリューム (24 時間):